See more : Alvotech (ALVO) Income Statement Analysis – Financial Results
Complete financial analysis of Unrivaled Brands, Inc. (UNRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Unrivaled Brands, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- L3Harris Technologies, Inc. (0L3H.L) Income Statement Analysis – Financial Results
- VSBLTY Groupe Technologies Corp. (VSBGF) Income Statement Analysis – Financial Results
- Bel Fuse Inc. (BELFA) Income Statement Analysis – Financial Results
- Jiangyin Pivot Automotive Products Co., Ltd. (301181.SZ) Income Statement Analysis – Financial Results
- Annaly Capital Management, Inc. (NLY) Income Statement Analysis – Financial Results
Unrivaled Brands, Inc. (UNRV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.unrivaledbrands.com
About Unrivaled Brands, Inc.
Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaled Brands, Inc. in July 2021. Unrivaled Brands, Inc. was founded in 2010 and is based in Santa Ana, California.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 52.02M | 47.67M | 14.29M | 28.05M | 31.33M | 35.80M | 25.33M | 9.98M | 7.09M | 2.13M | 552.58K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 35.12M | 35.71M | 10.69M | 13.40M | 18.90M | 30.32M | 22.76M | 8.96M | 6.94M | 2.04M | 451.71K | 0.00 | 0.00 | 0.00 |
Gross Profit | 16.90M | 11.97M | 3.60M | 14.65M | 12.43M | 5.48M | 2.57M | 1.02M | 152.99K | 88.92K | 100.87K | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 32.48% | 25.10% | 25.20% | 52.24% | 39.68% | 15.30% | 10.16% | 10.19% | 2.16% | 4.18% | 18.25% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 52.04M | 46.99M | 24.41M | 43.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.99K | 16.44K | 17.33K |
Selling & Marketing | 2.12M | 1.27M | 190.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 54.16M | 48.26M | 24.60M | 45.32M | 43.30M | 25.36M | 20.72M | 9.83M | 18.33M | 3.58M | 1.07M | 28.99K | 16.44K | 17.33K |
Other Expenses | 156.50M | -433.00K | 964.00K | 144.00K | 0.00 | 565.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 210.66M | 48.26M | 24.60M | 45.32M | 43.30M | 25.36M | 20.72M | 9.83M | 18.33M | 3.58M | 1.07M | 28.99K | 16.44K | 17.33K |
Cost & Expenses | 245.78M | 83.96M | 35.29M | 58.72M | 62.20M | 55.68M | 43.48M | 18.79M | 25.27M | 5.61M | 1.52M | 28.99K | 16.44K | 17.33K |
Interest Income | 4.17M | 1.78M | 1.39M | 9.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 4.17M | 1.78M | 2.93M | 9.30M | 13.09M | 2.68M | 1.79M | 1.17M | 1.10M | 1.28M | 62.20K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 13.40M | 8.96M | 964.00K | 6.29M | 4.98M | 3.65M | 2.54M | 645.29K | 438.78K | 41.31K | 14.09K | 0.00 | 0.00 | 0.00 |
EBITDA | -193.76M | -29.15M | -12.76M | -39.29M | -24.48M | -16.23M | -18.15M | -8.17M | -17.74M | -3.45M | -957.91K | -28.99K | -16.44K | -17.33K |
EBITDA Ratio | -372.51% | -57.33% | -140.25% | -86.91% | -84.74% | -45.34% | -71.65% | -81.92% | -250.00% | -162.08% | -173.35% | 0.00% | 0.00% | 0.00% |
Operating Income | -193.76M | -36.29M | -21.00M | -30.67M | -30.87M | -19.88M | -18.15M | -8.82M | -18.17M | -3.49M | -5.77M | -28.99K | -16.44K | -17.33K |
Operating Income Ratio | -372.51% | -76.12% | -147.00% | -109.33% | -98.52% | -55.53% | -71.65% | -88.39% | -256.19% | -164.03% | -1,044.55% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -1.87M | -5.89M | -9.12M | -17.77M | -8.60M | -13.65M | -9.84M | -546.10K | -3.99M | -2.66M | -63.53K | 0.00 | 0.00 | 0.00 |
Income Before Tax | -195.63M | -42.18M | -13.80M | -48.44M | -39.47M | -33.53M | -27.99M | -9.36M | -22.17M | -6.15M | -5.84M | -28.99K | -16.44K | -17.33K |
Income Before Tax Ratio | -376.11% | -88.47% | -96.59% | -172.70% | -125.98% | -93.66% | -110.49% | -93.86% | -312.46% | -289.14% | -1,056.05% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -2.78M | 885.00K | 13.04M | 6.87M | 279.61K | -347.46K | -1.07M | 44.00K | 13.46K | 1.65K | 879.00 | 28.99K | 16.44K | 17.33K |
Net Income | -192.85M | -43.06M | -26.84M | -55.31M | -39.75M | -32.68M | -26.92M | -9.23M | -21.89M | -6.15M | -5.84M | -28.99K | -16.44K | -17.33K |
Net Income Ratio | -370.76% | -90.33% | -187.88% | -197.17% | -126.87% | -91.28% | -106.28% | -92.48% | -308.55% | -289.22% | -1,056.21% | 0.00% | 0.00% | 0.00% |
EPS | -0.33 | -0.11 | -0.14 | -0.52 | -0.56 | -0.71 | -0.93 | -0.52 | -1.88 | -0.93 | -1.14 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -0.33 | -0.11 | -0.14 | -0.52 | -0.56 | -0.71 | -0.93 | -0.52 | -1.88 | -0.93 | -1.14 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 589.55M | 376.63M | 191.98M | 106.04M | 71.03M | 46.07M | 28.84M | 17.79M | 11.62M | 6.60M | 5.13M | 79.69M | 100.18M | 100.00M |
Weighted Avg Shares Out (Dil) | 589.55M | 376.63M | 191.98M | 106.04M | 71.03M | 46.07M | 28.84M | 17.79M | 11.62M | 6.60M | 5.13M | 79.69M | 100.18M | 100.00M |
Unrivaled Brands Announces Executive Appointments to Bring Korova, its Legacy Cannabis Brand, Back to Glory
Unrivaled Brands Announces Executive Appointments in Preparation for Planned Company Growth
Unrivaled Brands' Retail Dispensary, People's OC, Places in Top 3 “Best of Cannabis Retailers” in Orange County
Unrivaled Brands Continues Its Rise in the Cannabis Industry: Ranked #8 Most Profitable and #19 Most Credit Worthy Among U.S. and Canadian Peers
Unrivaled Brands Settles Litigation Brought Against Insurer and Broker, Reaffirms Focus on Market Opportunities
Unrivaled Brands, Inc. Details 10 Months of Turnaround Progress
Matt Barron, Cannabis Investor, Joins the Board of Directors at Unrivaled Brands
Unrivaled Brands Reports Second Quarter 2023 Financial Results
Unrivaled Brands Reports Second Quarter 2023 Preliminary Financial Results
Unrivaled Brands Appoints CEO as Chairman of the Board and COO as Director
Source: https://incomestatements.info
Category: Stock Reports